TNC
Tenascin
As of the edition of 20 October 2026, TNC (tenascin, UniProt P24821) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P24821
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 21
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Skin and connective tissue; Digestive system; Hormones; Immune system; Infections
- Registered trials of its drugs
- 7
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| F16IL2 | Stopped | Phase 2 | none listed |
| Tenatumomab | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Philogen | Route A |
| sigma-tau i.f.r | Route A |
The other 0 companies at TNC
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at TNC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.